Signals, Powered By EquityPandit
Glenmark Pharmaceuticals has received final approval for the generic version of Temovate cream used to treat inflammation and itching caused by a number of skin conditions, from the US health regulator.
In a BSE filing the company stated, “Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate cream USP, 0.05%, the generic version of Temovate Cream, 0.05% of Fougera pharmaceuticals.”
Moreover, the company’s current portfolio consists of 134 products authorized for distribution at the US marketplace and 61 abbreviated new drug applications (ANDA) pending approval with the USFDA.
